Charles River Laboratories to acquire Frontage bioanalysis and DMPK assets for $470 million
Charles River Laboratories (CRL) signed definitive agreements to buy Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations in Exton, Pennsylvania for cash of about $470 million, with up to $75 million in performance‑based earnout payments. The transaction includes two testing sites covering roughly 150,000 ft² and about 340 employees, and is expected to close in the first half of 2027 pending regulatory and shareholder approvals. CRL said the deal will expand its clinical bioanalysis capabilities and is projected to be neutral to non‑GAAP EPS in 2027 and accretive thereafter.
Why it matters
The acquisition adds roughly 40% of Frontage’s 2025 revenue ($256.7 million) to CRL’s Discovery and Safety Assessment segment, increasing its exposure to the fast‑growing bioanalysis market. Management expects the deal to be EPS‑neutral in 2027 and earnings‑accretive in later years, which could improve CRL’s profitability profile for investors.
Key facts
- 1CRL will pay approximately $470 million in cash for Frontage’s bioanalysis and DMPK operations. pharmaceutical-technology.com
- 2The transaction includes up to $75 million in performance‑based earnout payments. pharmaceutical-technology.com
- 3The assets consist of two testing facilities covering roughly 150,000 ft². finance.yahoo.com
- 4The facilities employ about 340 staff members. finance.yahoo.com
- 5Frontage’s Pennsylvania units generated around 40% of its total 2025 revenue of $256.7 million. pharmaceutical-technology.com
- 6The deal is expected to close in the first half of 2027, subject to regulatory clearances and shareholder approvals. pharmaceutical-technology.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.